Skip to main content
. 2019 Oct;113(4):737–745. doi: 10.5935/abc.20190169

Table 1.

Demographic, clinical and laboratory variables according to the group

Variable   NT (n = 11) PI (n = 24) NNRTI (n = 33) Control (n = 30) Kruskal-Wallis test (p)
Age (years) M ± DP 33.3 ± 4.1 44.8 ± 8.7 39.4 ± 8.0 49.9 ± 11.6 < 0.001
Md ± IQR 33.0 ± 3.0 43.0 ± 10.5 39.0 ± 8.0 48.5 ± 15.0  
Gender Male 9 (81.8%) 15 (62.5%) 14 (42.4%) 22 (73.3%) 0.033 (chi-square)
Female 2 (18.2%) 9 (37.5%) 19 (57.6%) 8 (26.7%)
Md ± IQR          
Heart rate (bpm) M ± SD 75.6 ± 7.3 72.0 ± 8.9 78.1 ± 6.2 73.2 ± 6.1 0.029
Md ± IQR 78.0 ± 14.0 73.5 ± 16.0 77.0 ± 9.5 75.0 ± 8.8  
SBP (mmHg) M ± SD 121.4 ± 6.0 129.3 ± 6.8 129.1 ± 6.8 123.8 ± 5.5 0.001
Md ± IQR 120.0 ± 5.0 130.0 ± 10.0 130.0 ± 5.0 125.0 ± 10.0  
DBP (mmHg) M ± SD 71.4 ± 4.5 70.0 ± 7.7 70.3 ± 7.5 67.8 ± 5.7 0.338
Md ± IQR 70.0 ± 5.0 70.0 ± 20.0 70.0 ± 15.0 70.0 ± 5.0  
Blood glucose (mg/dl) M ± SD 84.8 ± 14.2 79.7 ± 11.2 83.0 ± 9.5 82.4 ± 5.7 0.455
Md ± IQR 82.0 ± 23.0 79.0 ± 9.0 81.0 ± 13.5 81.0 ± 7.0  
Total cholesterol (mg/dL) M ± SD 164.6 ± 26.8 189.0 ± 56.3 183.9 ± 30.0 196.3 ± 17.4 0.021
Md ± IQR 163.0 ± 40.0 198.0 ± 54.0 181.0 ± 42.0 199.0 ± 26.0  
LDL-c (mg/dL) M ± SD 102.6 ± 27.6 108.7 ± 48.5 110.0 ± 27.9 118.9 ± 18.5 0.229
Md ± IQR 104.0 ± 49.0 109.0 ± 66.0 102.0 ± 36.0 122.0 ± 27.0  
HDL-c (mg/dL) M ± SD 47.5 ± 16.7 42.6 ± 17.5 55.0 ± 16.0 53.4 ± 3.5 0.007
Md ± IQR 43.0 ± 30.0 41.0 ± 22.0 52.0 ± 18.0 54.0 ± 4.0  
Triglycerides (mg/dL) M ± SD 101.1 ± 39.1 174.8 ± 78.2 119.7 ± 115.2 127.0 ± 15.5 < 0.001
Md ± IQR 86.0 ± 79.0 165.0 ± 106.0 87.0 ± 71.0 123.5 ± 27.0  
CD4+ lymphocytes/mm3 M ± SD 502.5 ± 206.3 534.4 ± 323.1 693.2 ± 317.7 - 0.044
Md ± IQR 426.0 ± 310.0 404.0 ± 436.0 644.0 ± 297.0 -  

M: mean; SD: standard deviation; Md: median; IQR: interquartile range; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; NT: HIV-positive patients not using antiretroviral therapy. PI: HIV-positive patients on protease inhibitor therapy. NNRTI: HIV-positive patients on non-nucleoside reverse transcriptase inhibitor therapy. Control: healthy HIV-negative individuals.